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Abstract
In previous work we showed that endothelin-1 (ET-1) increases the rate of glucose uptake in astrocytes, an important aspect
of brain function since glucose taken up by astrocytes is used to supply the neurons with metabolic substrates. In the
present work we sought to identify the signalling pathway responsible for this process in primary culture of rat astrocytes.
Our results show that ET-1 promoted an increase in the transcription factor hypoxia-inducible factor-1a (HIF-1a)i n
astrocytes, as shown in other cell types. Furthermore, HIF-1a-siRNA experiments revealed that HIF-1a participates in the
effects of ET-1 on glucose uptake and on the expression of GLUT-1, GLUT-3, type I and type II hexokinase. We previously
reported that these effects of ET-1 are mediated by connexin43 (Cx43), the major gap junction protein in astrocytes. Indeed,
our results show that silencing Cx43 increased HIF-1a and reduced the effect of ET-1 on HIF-1a, indicating that the effect of
ET-1 on HIF-1a is mediated by Cx43. The activity of oncogenes such as c-Src can up-regulate HIF-1a. Since Cx43 interacts
with c-Src, we investigated the participation of c-Src in this pathway. Interestingly, both the treatment with ET-1 and with
Cx43-siRNA increased c-Src activity. In addition, when c-Src activity was inhibited neither ET-1 nor silencing Cx43 were able
to up-regulate HIF-1a. In conclusion, our results suggest that ET-1 by down-regulating Cx43 activates c-Src, which in turn
increases HIF-1a leading to the up-regulation of the machinery required to take up glucose in astrocytes. Cx43 expression
can be reduced in response not only to ET-1 but also to various physiological and pathological stimuli. This study
contributes to the identification of the signalling pathway evoked after Cx43 down-regulation that results in increased
glucose uptake in astrocytes. Interestingly, this is the first evidence linking Cx43 to HIF-1, which is a master regulator of
glucose metabolism.
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Introduction
Endothelins (ET-1, ET-2 and ET-3) are vasoactive peptides
found in many tissues [1]. The first member of this family, ET-1 is
present in brain endothelial cells [2], neurons [3], and astrocytes
[4], and its secretion increases in several pathologies, such as
cerebral ischemia [5], Alzheimer disease [6], HIV infection [7,8],
reactive gliosis [4,9,10] and astrocytic tumours [11]. In astrocytes,
ET-1 behaves as a growth factor, exerting important biological
effects such as changes in protein content and morphology [12],
the induction of proliferation [13,14,15,16] and the increase in the
rate of glucose uptake [16,17,18].
The regulation of glucose uptake in astrocytes is an important
aspect of brain function since glucose taken up by astrocytes is
used not only by astrocytes but also to supply the neurons with
metabolic substrates required to sustain synaptic transmission
[19,20]. Astrocytes are connected through gap junctions [21],
composed mainly of connexin43 (Cx43) [22]. This intercellular
communication provides the basis for several important astrocytic
functions [23]. For instance, gap junction channels allow the
passage from cell to cell of glucose and other metabolites,
contributing to the distribution of metabolic substrates from blood
to different regions [17,20,23]. Various physiological and
pathological signals promote changes in gap junctional commu-
nication and Cx43 expression (for a review, see [23]). One of these
signals is ET-1, which rapidly inhibits gap junctional communi-
cation between astrocytes and after long-term exposure (24 h)
causes the down-regulation of Cx43 [24,25]. In fact, we have
shown that the down-regulation of Cx43 exerted by ET-1 is
involved in the increase in the rate of glucose uptake observed in
astrocytes [26]. This effect includes the up-regulation of the
glucose transporter GLUT-1 and the induction of GLUT-3, an
isoform not normally expressed in astrocytes [18,26]. Intracellular
glucose is quickly phosphorylated by hexokinase (Hx) to glucose-6-
phosphate, which is a charged molecule that cannot pass back
through the plasma membrane and becomes trapped within the
cell. Both type I (Hx-1) and type II (Hx-2) hexokinase are up-
regulated by ET-1 in astrocytes [18,26].
Hypoxia-Inducible Factor (HIF)-1a/b heterodimer is a master
transcription factor for several genes involved in glucose uptake,
angiogenesis, glycolysis, pH balance and metastasis. Among the
genes activated by HIF-1 are GLUT-1, GLUT-3, Hx-1 and Hx-2
(revised in [27]). While HIF-1b is stable and constitutively
expressed, HIF-1a is highly regulated, as well as susceptible to
oxygen-dependent degradation due to the sequential action of
oxygen-dependent prolyl hydroxylases and the VHL ubiquitin
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dimerizes with HIF-1ß and activates target genes. It should be
mentioned that although HIF is mainly activated under hypoxia,
several factors activate HIF-1a under normoxic conditions.
Intriguingly, endothelins are among the factors with the ability
to activate HIF-1a under normoxic conditions in melanoma and
ovarian carcinoma cells [28,29,30]. Furthermore, oncogenes, such
as c-Src prevent hydroxylation-dependent ubiquitinylation of HIF-
1a, thus stabilizing it under normoxic conditions [31,32,33].
The intracellular carboxyl tail of Cx43 interacts with a large
number of signalling and scaffolding proteins [34,35], thereby
regulating cell functions such as cell adhesion, migration and
proliferation [36,37,38,39]. One of these interacting proteins is the
non-receptor tyrosine kinase c-Src [40,41,42]. Interestingly, we
have recently shown that the interaction between Cx43 and c-Src
promotes the inactivation of the oncogenic activity of c-Src [43].
Although it is well described that ET-1 increases the rate of
glucose uptake by a Cx43-dependent mechanism that includes the
up-regulation of GLUT-1, GLUT-3, Hx-1 and Hx-2 [18,26], so
far there have been no studies examining the mechanism by which
Cx43 regulated these genes. Since GLUT-1, GLUT-3, Hx-1 and
Hx-2 are targets of the transcription factor HIF-1a, and this factor
can be activated by c-Src, which interacts with Cx43, in this work
we aimed to investigate the participation of HIF-1a and c-Src on
ET-1 modulation of the rate of glucose uptake in astrocytes.
Results
ET-1 up-regulates HIF-1a by decreasing Cx43 expression
in astrocytes
In previous work we showed that ET-1 increased the rate of
glucose uptake in astrocytes. Thus, ET-1 up-regulated GLUT-1
and Hx-1 and induced the expression of isoforms not normally
expressed in astrocytes, such as GLUT-3 and Hx-2 [18,26]. Since
these proteins are target genes of HIF-1a, in this work we
investigated whether the treatment with ET-1 modified HIF-1a
levels in astrocytes, as it has been shown in other cell types
[28,29,30]. Our results show that the treatment with 0.1 mM ET-1
strongly increased (by about 150%) the levels of HIF-1a
(Figures 1A and B). This effect was evident after two hours of
treatment and persisted for at least 48 h.
The inhibition of gap junctional communication promoted by
ET-1 in astrocytes is well documented [12,16,17,44,45,46,47].
Thus, ET-1 triggers very fast changes (within 3–10 minutes) in the
gap junctional communication and in the phosphorylation status
of Cx43 [48]. Changes in gap junctional communication and in
the phosphorylation status of Cx43 are associated with changes in
Cx43 interaction with other proteins and with Cx43 endocytosis
[41,42,48]. Thus, a prolonged (24 hours) exposure to ET-1
reduces Cx43 expression in astrocytes [24,25]. Interestingly, the
down-regulation of Cx43 promoted by ET-1 coincided with the
up-regulation of HIF-1a (Figure 1C). Since our previous work
indicated that the effect of ET-1 on glucose uptake was due to the
reduction in Cx43 expression, we investigated the effect of
decreasing Cx43 expression on HIF-1a levels. Thus, by using
specific siRNA against Cx43 [26,43] we found that 48 h after the
transfection with Cx43-siRNA the level of Cx43 was reduced by
about 50% (Figures 2A and 2C) and the expression of HIF-1a was
increased by about 80% (Figure 2B), when compared to astrocytes
transfected with a non-targeting siRNA (NT-siRNA). Consequent-
ly, our results show that silencing Cx43 up-regulated HIF-1a.I n
addition, Figure 3 shows that the difference in HIF-1a levels
between ET-1 and the control was not statistically significant in
cells transfected with Cx43-siRNA, indicating that ET-1 was not
able to further increase significantly the levels of HIF-1a in Cx43-
silenced astrocytes.
HIF-1a mediates the increase in glucose uptake
promoted by ET-1
Since our results indicate that the axis ET-1/Cx43 up-regulates
HIF-1a, which is a transcription factor involved in the regulation
of glucose uptake, our next goal was to investigate the participation
of HIF-1a in the increase in the rate of glucose uptake promoted
by ET-1 in astrocytes. To do so, the expression of HIF-1a was
down-regulated by 3 different and specific siRNAs against HIF-1a
(HIF-1a-siRNA) and the results compared with those obtained
with NT-siRNA. Our results show that 48 h after the transfection
with HIF-1a-siRNA the expression of HIF-1a was reduced by
about 50% when compared with NT-siRNA (Figure 4A) and this
effect persisted for at least 72 h (Figure S1). Next, the effect of ET-
1 was tested in astrocytes transfected with NT-siRNA or with HIF-
1a-siRNA for 48 h. Our results show that the up-regulation of
Figure 1. Effect of ET-1 on the expression of HIF-1a in
astrocytes. Astrocytes were incubated in the absence (control) or
presence of 0.1 mM ET-1 for the indicated times. Then, the expression of
HIF-1a and Cx43 was analysed by Western blot. A) Representative
Western blot of HIF-1a, Cx43 and GAPDH showing that ET-1 up-
regulated HIF-1a and down-regulated Cx43. B) HIF-1a quantification. C)
Cx43 quantification. The results are expressed as percentages of the
level found in the controls at time 0. ***p,0.001 versus the
corresponding controls.
doi:10.1371/journal.pone.0032448.g001
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siRNA was reduced in HIF-1a-silenced astrocytes (Figure 4A). In a
similar way, silencing HIF-1a strongly reduced the up-regulation
of GLUT-1, GLUT-3, Hx-1 and Hx-2 promoted by ET-1 in
astrocytes transfected with NT-siRNA (Figure 4A). Importantly,
this effect was also observed when the rate of glucose uptake was
analyzed. Thus, the rate of glucose uptake was reduced by HIF-
1a-siRNA both in the control and in the ET-1 treated astrocytes
(Figure 4B), suggesting that HIF-1a participates in the effect of
ET-1 on glucose uptake.
c-Src mediates the increase in glucose uptake promoted
by ET-1
Our recent work shows a direct relationship between Cx43 and
c-Src activity [43]. Since c-Src has been shown to up-regulate
HIF-1a [31,32,33], we investigated whether c-Src mediates the
effect of ET-1 and Cx43 on glucose uptake. To measure c-Src
activity we analysed the levels of c-Src phosphorylated at Tyr-416
(Y416 c-Src), the active form of this tyrosine kinase [49,50]. Our
results show that ET-1 transiently increased c-Src activity. Thus,
ET-1 rapidly increased Y416 c-Src (within 6 minutes) and this
effect was maintained for two hours, decreasing thereafter
(Figure 5A). Meanwhile, the total amount of c-Src remained
constant. Interestingly, silencing Cx43 also increased c-Src activity
without changing the amount of total c-Src (Figure 5B).
In order to investigate whether the activation of c-Src was
responsible for HIF-1a up-regulation, the activity of c-Src was
inhibited by PP2 and the inactive analogue PP3 was used as a
control. Thus, while in the presence of PP3, ET-1 immediately
increased c-Src activity, in the presence of PP2 the effect of ET-1
on c-Src was abrogated (Fig. 6). Next, the effect of ET-1 and Cx43
on HIF-1a was tested when c-Src was inhibited by PP2. Our
results show that ET-1 was not able to up-regulate HIF-1a
(Figure 7A) when c-Src was inhibited by PP2. Interestingly, the
effect of ET-1 on the rate of glucose uptake was abrogated when c-
Src was inhibited by PP2 (Figure 7B). Finally, our results show that
silencing Cx43 did not up-regulate HIF-1a when the activity of c-
Src was inhibited by PP2 (Figure 7C).
Discussion
Endothelins are involved in several important pathologies of the
CNS such as ischemia, gliomas, reactive gliosis and Alzheimer’s
disease. One of their targets in the CNS is astrocytes, in which
endothelins exert a broad range of biological effects. In this sense,
the mitogenic effect of ET-1, its ability to inhibit gap junctional
communication, to down-regulate Cx43, the protein forming gap
junction channels, and to increase the rate of glucose uptake is well
known [14,15,16,44]. In previous work we showed that ET-1
Figure 2. Effect of silencing Cx43 on the expression of HIF-1a in
astrocytes. Astrocytes were transfected with NT-siRNA or with Cx43-
siRNA. At the indicated times the expression of HIF-1a and Cx43 was
analysed by Western blot. A) Representative Western blot of HIF-1a,
Cx43 and GAPDH showing that the decrease in Cx43 expression was
concomitant with HIF-1a up-regulation. B) HIF-1a quantification. C)
Cx43 quantification. The results are expressed as percentages of the
level found in the NT-siRNA condition at time 0. ***p,0.001 versus the
corresponding NT-siRNA values.
doi:10.1371/journal.pone.0032448.g002
Figure 3. Effect of ET-1 on the expression of HIF-1a in Cx43-
silenced astrocytes. Astrocytes were transfected with NT-siRNA or
with Cx43-siRNA as indicated. After 48 h, cells were incubated in the
absence (control, C) or presence of 0.1 mM ET-1 for 24 h. HIF-1a levels
were analysed by Western blot. Note that the differences between ET-1
and Control in Cx43-silenced astrocytes were lower than those found
between ET-1 and Control in NT-siRNA or in non-transfected astrocytes.
The results are expressed as percentages of the level found in control
non-transfected cells. ***p,0.001 versus the corresponding controls;
#p,0.05 versus the corresponding non-transfected cells. n.s. not
significant.
doi:10.1371/journal.pone.0032448.g003
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that includes the up-regulation of the glucose transporters GLUT-
1 and GLUT-3 and the enzymes required to phosphorylate
glucose, Hx-1 and Hx-2 [18]. In the present study we sought
deeper into the signalling pathway responsible for this process.
Our results show that ET-1 promoted an increase in the levels of
HIF-1a in astrocytes under normoxic conditions, as it has been
previously shown in melanoma and ovarian carcinoma cells
Figure 4. Effect of ET-1 on glucose uptake in HIF-1a-silenced astrocytes. Astrocytes were transfected with NT-siRNA or with HIF-1a-siRNA.
After 48 h, astrocytes were incubated in the absence (control, C) or presence of 0.1 mM ET-1 for 24 h. A) HIF-1a, Hx-1, GLUT-3, Hx-2, GLUT-1 and
GAPDH Western blots and quantification. The results are the means 6 SEM of at least three independent experiments and they are expressed as
percentages of the level found in the control NT-siRNA. B) Glucose uptake expressed as pmol of 2-deoxyglucose (2-DG) taken up per hour and per
milligram of protein. The results show that the down-regulation of HIF-1a levels promoted by HIF-1a-siRNA decreased the rate of glucose uptake and
the expression of GLUT-1, GLUT-3, Hx-1 and Hx-2, both in the control and in the ET-1 treated astrocytes. ***p,0.001, **p,0.01 and *p,0.05 versus
the corresponding controls (C);
###p,0.001,
##p,0.01 and
#p,0.05 versus the corresponding NT-siRNA.
doi:10.1371/journal.pone.0032448.g004
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ET-1 on GLUT-1, GLUT-3, Hx-1, Hx-2 and on the rate of
glucose uptake were strongly reduced. Since HIF-1a is a
transcription factor for GLUT-1, GLUT-3, Hx-1 and Hx-2
[27], it could be proposed that the effect of ET-1 on the rate of
glucose uptake in astrocytes is mediated by HIF-1a.
We have previously shown that the effect of ET-1 on glucose
uptake is mediated by the reduction in the expression of Cx43
[26]. Agreeing with this, in this study we show that silencing Cx43
promoted an increase in the levels of HIF-1a and reduced the
effect of ET-1 on HIF-1a, indicating that Cx43 participates in the
effect of ET-1 on HIF-1a. Cx43 is the main protein forming gap
junction channels in astrocytes, which implies that the protein is
critical for important functions of astrocytes in the brain [23,51].
In fact, Cx43 expression can be reduced in response not only to
ET-1 but also to various physiological and pathological stimuli (for
a review, see [23]). This study contributes to the identification of
the signalling pathway evoked after Cx43 down-regulation that
results in increased glucose uptake in astrocytes. In this sense,
although the relationship between Cx43 and several signalling
pathways is well known [34], so far this is the first evidence
showing a relationship between Cx43 and HIF-1a.
HIF-1a is mainly regulated by hypoxia but it can also be up-
regulated by several mechanisms, including the activity of c-Src
[31,32,33], a non-receptor tyrosine kinase involved in the
regulation of cell proliferation. Interestingly, the intracellular
carboxyl tail of Cx43 interacts with c-Src [40,41,42], and this
interaction modulates reciprocally their activities. Thus, phos-
phorylation of Cx43 by c-Src reduces gap junctional communi-
cation [40,52,53] while the increase in Cx43 levels inhibits c-Src
activity, at least in rat glioma cells [43]. Agreeing with this, our
results show that both the treatment with ET-1 and with Cx43-
siRNA increased c-Src activity in astrocytes. In addition, when c-
Src activity was inhibited neither ET-1 nor silencing Cx43 were
Figure 5. Effect of ET-1 and Cx43 on c-Src activity in astrocytes. A) Astrocytes were incubated in the absence (control, C) or presence of
0.1 mM ET-1 for the indicated times, proteins were extracted and Y416 c-Src and total c-Src were analysed by Western blot. The results are expressed
as percentages of the level found in the control and they show that ET-1 rapidly and transiently increased Y416 c-Src without affecting significantly
total c-Src. ***p,0.001; *p,0.05 versus control. B) Astrocytes were transfected with NT-siRNA or with Cx43-siRNA. After 48 h, proteins were extracted
and Y416 c-Src, total c-Src and Cx43 were analysed by Western blot. The results are expressed as percentages of the level found in the control and
they show that silencing Cx43 increased Y416 c-Src without affecting significantly total c-Src. **p,0.01 versus NT-siRNA.
doi:10.1371/journal.pone.0032448.g005
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glucose uptake was abrogated when c-Src is inhibited. It is well
documented that the inhibition of gap junctional communication
in astrocytes promoted by ET-1 and other gap junction uncouplers
increases proliferation and glucose uptake [16,18,24,26], however
the molecular mechanism linking these cellular events is unknown.
In this study we provide evidence that c-Src is activated by ET-1
and by silencing Cx43. c-Src is a well known regulator of cell
proliferation [54] and this study and the work carried out by other
laboratories [31,32,33] show that c-Src can activate HIF-1a and
consequently glucose uptake. Therefore, it could be proposed that
c-Src could be the mediator that links the increase in cell
proliferation and glucose uptake found in astrocytes after
inhibiting gap junctional communication or reducing Cx43
expression.
Furthermore, our results confirm that the level of Cx43
expression is important to regulate c-Src activity. Thus, the up-
regulation of Cx43 in glioma cells reduces the high c-Src activity
found in these cells [43], while in this study we show that silencing
Cx43 activates c-Src in astrocytes. It should be mentioned that this
effect could be due to the absence of Cx43 function (gap junctional
communication) or to the absence of Cx43 interaction with other
proteins, such as c-Src. Changes in Cx43 expression are
accompanied by changes in cell proliferation, thus restoration of
Cx43 in glioma cells decreases the rate of proliferation
[43,51,55,56], while silencing Cx43 increases the rate of astrocyte
proliferation [26]. Consequently, it could be proposed that the
interaction between Cx43 and c-Src could be an important step in
the regulation of cellular events, such as cell proliferation. In this
context, the interaction between Cx43 and c-Src has been
proposed to be responsible for the regulation of P2Y1 purinergic
receptors, which are involved in glial calcium signal transmission
and in the migration of neural progenitor cells [57]. Together,
these data suggest a relevant role of the interaction between Cx43
and c-Src in the CNS.
As mentioned above, endothelins are involved in several
pathologies of the CNS such as gliomas [11]. It should be
mentioned that reduced expression of Cx43 [58,59,60,61], high c-
Src activity [62] and activation of the HIF-1 pathway [63] are all
common features of gliomas. In addition, glioma cells, like many
other cancer cells adapt their metabolism to the tumour en-
vironment, a process known as ‘‘Warburg Effect’’ that begins by
an increase in the rate of glucose uptake and a metabolic shift to
aerobic glycolysis, which is associated with a survival advantage as
well as the generation of substrates necessary in rapidly
proliferating cells [64]. For instance, enzymes such as Hx-2 are
key mediators of aerobic glycolisis and promote tumour growth in
gliomas [65]. In this study, we suggest that these events could be
linked in a common pathway. Thus, our results suggest that ET-1
by down-regulating Cx43 activates c-Src, which in turn up-
regulates HIF-1a leading to the transcription of the machinery
required to increase the rate of glucose uptake in astrocytes
(Figure 8). These metabolic changes are probably designed to
sustain the higher rate of cell proliferation observed under these
circumstances [66]. ET-1 participates in the progression of
different tumours [67], however, whether the presence of ET-1
in gliomas [11] activates the pathway reported in this study
(Figure 8) to promote the growth and progression of these tumours
remains to be elucidated and warrant further exploration.
Materials and Methods
Materials
Dulbecco’s modified Eagle medium (DMEM), penicillin,
streptomycin, poly-L-lysine, ET-1, and protease inhibitors were
obtained from Sigma-Aldrich Chemical Co. (Madrid, Spain). Fetal
calf serum (FCS), DNase, bovine serum albumin and trypsin were
from Boehringer Mannheim (Barcelona, Spain). Optimen and
Lipofectamine 2000 were purchased from Invitrogen (Barcelona,
Spain). Monoclonal antibody against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and small interfering RNAs (siRNAs)
were obtained from Genelink (New York, USA). 2-Deoxy-
D[1-
14C]glucose was from Amersham Pharmacia Biotech (Barce-
lona, Spain). The c-Src inhibitor, PP2 and the control PP3 were
obtained from Calbiochem (Nottingham, United Kingdom).
Mouse monoclonal antibody against Cx43 (610062) was from
Transduction Laboratories, Inc. (BD Bioscience Pharmigen, San
Diego, CA, U.S.A.). Mouse monoclonal antibody against Hx-1
(MAB1532) and Hx-2 (MAB1629) and rabbit polyclonal antibody
Figure 6. Inhibition of c-Src activity in astrocytes by PP2.
Astrocytes were preincubated with 100 ng/mL PP2 (c-Src inhibitor) or
100 ng/mL PP3 (inactive analogue) for 1 h and these agents were
maintained for the rest of the experiment. Then, cells were incubated in
the absence or presence of 0.1 mM ET-1 for the indicated times and
proteins were extracted for the analysis of Y416 c-Src and total c-Src by
Western blot. The results are expressed as percentages of the level
found in the control (PP3, time 0) and they show that PP2 inhibited the
activation of c-Src (Y416 c-Src) promoted by ET-1. ***p,0.001; *p,0.05
versus the corresponding time 0.
doi:10.1371/journal.pone.0032448.g006
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Chemicon International Inc (Madrid, Spain). Rabbit polyclonal
antibody against total c-Src (2108) and rabbit polyclonal antibody
against Y416 c-Src (2101) were from Cell Signaling Technology
(Boston, EEUU). Rabbit polyclonal antibody against HIF-1a
(NB100-479) was from Novus Biologicals (Colorado, EEUU).
Polyvinylidene fluoride membranes (PVDF) were from Millipore
Corporation (Bedford, U.S.A.). The Bio-Rad protein assay and
polyacrylamide were from Bio-Rad (Madrid, Spain). X-ray films
were from Fujifilm (Madrid, Spain). Other chemicals were
purchased from Sigma-Aldrich Chemical Co. (Madrid, Spain) or
Merck (Barcelona, Spain).
Animals
Albino Wistar rats, fed ad libitum on a stock laboratory diet
(49.8% carbohydrates, 23.5% protein, 3.7% fat, 5.5% wt/vol
minerals and added vitamins and amino acids), were used for the
experiments. Rats were maintained on a 12-h light–dark cycle.
Postnatal day 1 newborn rats were used to prepare astrocyte
cultures. The animals were obtained from the animal facility of the
University of Salamanca and their use for this study was approved
by the bioethics committee of this institution.
Cell cultures
Astrocytes in primary culture were prepared from the forebrains
of 1- to 2-day-old Wistar rats as previously described [68]. Briefly,
animals were decapitated and their brains immediately excised.
After removing the meninges and blood vessels, the forebrains
were placed in Earle’s balanced solution containing 20 mg/mL
DNase and 0.3% (w/v) bovine serum albumin. The tissue was
minced, washed, centrifuged and incubated in 0.025% (w/v)
trypsin and 60 mg/mL DNase for 15 min at 37uC in a shaking
water bath. Trypsinization was completed by adding DMEM
containing 10% (v/v) FCS. The tissue was then dissociated by
Figure 7. Effect of ET-1 and Cx43 on HIF-1a expression and glucose uptake when c-Src is inhibited. Astrocytes were preincubated with
100 ng/mL PP2 (c-Src inhibitor) or 100 ng/mL PP3 (inactive analogue) for 1 h. Then, cells were incubated in the absence (control) or presence of
0.1 mM ET-1 for 24 h. A) HIF-1a Western blot and quantification. The results are expressed as percentages of the level found in the controls treated
with PP3 and they show that the inhibitor of c-Src PP2 prevented the up-regulation of HIF-1a promoted by ET-1. ***p,0.001 versus the absence of
ET-1. B) Glucose uptake expressed as pmol of 2-deoxyglucose taken up per hour and per milligram of protein. The results show that the inhibitor of c-
Src PP2 prevented the increase in the rate of glucose uptake promoted by ET-1. ***p,0.001 versus the absence of ET-1. C) Astrocytes were
preincubated with 100 ng/mL PP2 or 100 ng/mL PP3 for 1 h. Then, cells were transfected with NT-siRNA or with Cx43-siRNA and after 48 h HIF-1a was
analysed by Western blot. The results are expressed as percentages of the level found in the PP3 NT-siRNA and they show that the inhibitor of c-Src
PP2 prevented the up-regulation of HIF-1a promoted by silencing Cx43. ***p,0.001 versus the corresponding NT-siRNA.
doi:10.1371/journal.pone.0032448.g007
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pipette, and the supernatant cell suspension was recovered. This
procedure was repeated and the resulting cell suspension was cen-
trifuged. The culture medium was DMEM (with 5 mM glucose)
supplemented with 10% (v/v) FCS, penicillin (50 U/mL) and
streptomycin (50 mg/mL). The cell pellet was resuspended in a
known volume of culture medium and plated onto poly-L-lysine-
coated Petri dishes or flasks at a density of 1.5610
5 cells/cm
2.
Cells were incubated at 37uC in an atmosphere of 95% air/5%
CO2 with 90–95% humidity. After 3 days, cytosine arabinoside
(10 mM) was added to the culture medium for 2 days to prevent
the growth of microglia and cells from the O-2 lineage. The
culture medium was renewed with a fresh one twice a week. Under
our experimental conditions, 90–95% of the cells were astrocytes
as determined by immunostaining against glial fibrillary acidic
protein [69,70,71]. Experiments were carried out after 21 days in
culture.
Cell treatments
The compounds tested were 0.1 mM ET-1, 100 ng/mL PP3 or
100 ng/mL PP2. PP2 and PP3 were preincubated for 1 hour and
were present in the solutions used throughout the experiments.
Incubations were performed for the indicated times in culture




were transfected with the double-strand siRNA (50 nM) complexed
with 2.5 ml/ml Lipofectamine 2000 in culture medium without
antibiotics. The sequences of siRNAs were as follow: Cx43-siRNA:
sense 59-gcugguuacuggugacagatt-39 and antisense 59-ucugucacca-
guaaccagctt-39;H I F - 1 a siRNA: 59-cugauaacgugaacaaauatt-39 and
antisense 59-uauuuguucacguuaucagtt-39 and a validated NT-siRNA
provided by Ambion used as a negative control. Other siRNA
sequences for HIF-1a were tested (sense 59-cauugaagaugaaaugaaatt-
39, antisense 59-uuucauuucaucuucaaugtt-39 and sense 59-cuguugau-
cuuauaaugautt-39, antisense 59-aucauuauaagaucaacagtt-39)a n dt h e
same phenotype was observed (Figure S1). The cells were
maintained in the presence of the oligonucleotides in culture
medium without antibiotics and after 6 h, the medium was replaced
with DMEM plus 10% FCS with antibiotics. The extent of siRNA-
mediated down-regulation of protein expression was evaluated in
Western blots. Cell treatments were performed 48 hours after
siRNA transfections.
2-Deoxyglucose uptake
Conditions were similar to those reported previously [17,18,26].
After the indicated treatments, cells were incubated with DMEM
containing 2-deoxy-D[1-
14C]glucose (750 dpm/pmol) for 30 min.
Then, cells were washed with ice-cold PBS and were lysed by
adding 500 mL of 10 mM NaOH containing 0.1% Triton X-100.
An aliquot was assayed for [
14C] by liquid scintillation counting
(efficiency 95%) and another aliquot was used to measure protein
concentration.
Western blotting
Twenty-four hours after the treatments, proteins were extracted
from the cells using 2% sodium dodecyl sulphate (SDS) in 5 mM
Tris–HCl, pH 6.8, containing 2 mM EGTA, 2 mM EDTA,
2 mM phenylmethylsulphonyl fluoride, 0.5 mg/mL antipain,
0.5 mg/mL pepstatin, 0.5 mg/mL amastatin, 0.5 mg/mL leupep-
tin, 0.5 mg/mL bestatin, 0.5 mg/mL of trypsin inhibitor, sodium
fluoride (NaF) 1 mM and sodium orthovanadate (Na3VO4)
100 mM. The protein extract (80 mg) was applied to a 10%
SDS–Polyacrilamide gel under reducing conditions and then
Figure 8. Proposed mechanism. Since Cx43 inhibits c-Src activity [43], it could be proposed that ET-1 by reducing Cx43 activates c-Src, which in
turn increases HIF-1a. HIF-1a dimerizes with HIF-1ß and translocates to the nucleus. The transcriptional activity of HIF induces the synthesis of the
machinery required to augment the rate of glucose uptake in astrocytes, i.e., the glucose transporters, GLUT-1 and GLUT-3 and the enzymes required
for glucose phosphorylation, type I and type II hexokinase (Hx-1 and Hx-2).
doi:10.1371/journal.pone.0032448.g008
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several strips to be immunoblotted with distinct antibodies, thus
allowing for comparative analysis of the amount of each protein in
the same sample. Membranes were then blocked with 10% fat-free
dried milk in TTBS and then exposed to primary antibody against
Cx43 (1:100), Hx-1 (1:500), Hx-2 (1:500), GLUT-1 (1:500),
GLUT-3 (1:500), c-Src (1:500), Y416 c-Src (1:500) or HIF-1a
(1:500), for at least 4 h. Mouse antibody against GAPDH (1:5000)
was used as a loading control. Peroxidase-conjugated anti-rabbit
IgG or peroxidase conjugated anti-mouse IgG were used and
developed with a chemiluminiscent substrate. Membranes were
exposed to X-ray films. When necessary, blots were stripped and
re-probed with other antibodies. X-ray films were scanned and
densitometry analysis of the bands was performed using image-
analyzer software (SCION IMAGE, based on NIH Image, Wayne
Rasband, National Institutes of Health, Bethesda, MD, USA). The
amounts of GAPDH recovered in each sample served as loading
control and the values for each protein were normalized to their
corresponding GAPDH level. The results are expressed as
percentages of the values found in the controls.
Protein Determinations
Protein concentrations were determined by the Bradford
method [72], using bovine serum albumin (BSA) as the standard.
Statistical analyses
The results are the means 6 S.E.M. of at least three
independent experiments. Statistical analyses were carried out
with Student’s t-test or One-Way ANOVA followed by Tukey test
when comparing more than two variables. Values were considered
significant when p,0.05.
Supporting Information
Figure S1 Silencing HIF-1a in astrocytes by siRNA.
Astrocytes were transfected with NT-siRNA or with 3 different
sequences of siRNA specific for HIF-1a (sequence 1: sense 59-
cauugaagaugaaaugaaatt-39, antisense 59-uuucauuucaucuucaaugtt-
39; sequence 2: sense 59-cugauaacgugaacaaauatt-39 and antisense
59-uauuuguucacguuaucagtt-39; sequence 3: sense 59-cuguugau-
cuuauaaugautt-39 and antisense 59-aucauuauaagaucaacagtt-39). At
the indicated times the proteins were extracted and HIF-1a levels
were analysed by Western blot. The results are expressed as
percentages relative to the level found in cells transfected with NT-
siRNA. ***p,0.001 versus NT-siRNA. Sequence 2 was selected
for the following experiments because it showed the higher down-
regulation after 48 h and the reduction was maintained for 72 h.
(TIF)
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